csirt@kutim:~/threat-intel/cve/CVE-2026-18149

Katalog CVE

CVSS 5.9 · Medium EPSS 0,36%

Kerentanan Missing Release of Resource after Effective Lifetime pada nodejs undici. Skor CVSS 3.1 5.9 (Medium) menurut CNA.

Deskripsi (NVD)

undici's retry handler can leave an already-exposed response body pending forever. When a server returns a successful response that declares a Content-Length, sends only part of the body, and closes the connection, the retry handler retries the request. If the retry returns a non-retryable status such as 400, the handler forwards that new response downstream and replaces its internal response stream, but the original response body that the application still holds is never ended or destroyed. As a result calls that read that body never settle, and the configured body timeout does not fire because its timer is tied to the connection parser rather than the orphaned body. An attacker-controlled server can trigger this with two short responses without keeping a connection open, and repeated requests accumulate pending promises and streams that can exhaust application concurrency or memory. This affects undici versions from 7.11.0 up to 7.29.1 and from 8.0.0 up to 8.10.2. Users should upgrade to undici 7.29.1 or 8.10.2.

Rincian

Terbit di NVD
4 September 2026
Terakhir diubah
16 September 2026
Status NVD
Analyzed
CVSS 3.1
5.9 (Medium), sumber CNA
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-772: Missing Release of Resource after Effective Lifetime
EPSS (30 hari)
0,36% peluang dieksploitasi; lebih tinggi dari 27,9% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
nodejs undici Versi 7.11.0 hingga sebelum 7.29.1
nodejs undici Versi 8.0.0 hingga sebelum 8.10.2

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.